Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
It has long been observed in clinical practice that a subset of patients with Lyme disease report a constellation of symptoms such as fatigue, cognitive difficulties, and musculoskeletal pain, which may last for a significant period of time. These symptoms, which can range from mild to severe, have been reported throughout the literature in both prospective and population-based studies in Lyme disease endemic regions. The etiology of these symptoms is unknown, however several illness-causing mechanisms have been hypothesized, including microbial persistence, host immune dysregulation through inflammatory or secondary autoimmune pathways, or altered neural networks, as in central sensitization. Evaluation and characterization of persistent symptoms in Lyme disease is complicated by potential independent, repeat exposures to B. burgdorferi, as well as the potential for co-morbid diseases with overlapping symptom profiles. Antibody testing for B. burgdorferi is an insensitive measure after treatment, and no other FDA-approved tests currently exist. As such, diagnosis presents a complex challenge for physicians, while the lived experience for patients is one marked by uncertainty and often illness invalidation. Currently, there are no FDA-approved pharmaceutical therapies, and the safety and efficacy of off-label and/or complementary therapies have not been well studied and are not agreed-upon within the medical community. Post-treatment Lyme disease represents a narrow, defined, mechanistically-neutral subset of this larger, more heterogeneous group of patients, and is a useful definition in research settings as an initial subgroup of study. The aim of this paper is to review the current literature on the diagnosis, etiology, risk factors, and treatment of patients with persistent symptoms in the context of Lyme disease. The meaning and relevance of existing patient subgroups will be discussed, as will future research priorities, including the need to develop illness biomarkers, elucidate the biologic mechanisms of disease, and drive improvements in therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concepts of trust among patients with serious illness
Mechanic, D., & Meyer, S. (2000) · Social Science & Medicine · doi:10.1016/s0277-9536(00)00014-9 · Cited by 617
Haugmark, T., Hagen, K. B., Smedslund, G., & Zangi, H. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221897 · Cited by 161 · cited 1×
“Mindfulness-based stress reduction has been tested among patients with fibromyalgia and shows promise in reducing both symptoms and stress levels (165).”
BackgroundChronic fatigue: symptom and syndrome
Wessely, S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-9_part_2-200105011-00007 · Cited by 136
Cited by
Multiple early factors anticipate post-acute COVID-19 sequelae
Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.014 · Cited by 1,156
“Future studies of other ‘‘long’’ medical conditions, such as post-treatment Lyme disease (Rebman and Aucott, 2020), ‘‘chemobrain’’ (Nguyen and Ehrlich, 2020), and postICU syndrome (Brown et al.”
Proal, A. D., & VanElzakker, M. B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698169 · Cited by 876
Unexplained post-acute infection syndromes
Choutka, J., Jansari, V., Hornig, M., & Iwasaki, A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01810-6 · Cited by 604
Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022) · Biochemical Journal · doi:10.1042/bcj20220016 · Cited by 271
Haugmark, T., Hagen, K. B., Smedslund, G., & Zangi, H. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221897 · Cited by 161
Metadata
- Authors
- Rebman, A. W., & Aucott, J. N.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-02-25
- Volume
- 7
- Pages
- 57-57
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W3007115356
- Cited by
- 155
- References
- 3
- FWCI
- 16.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.